AR047702A1 - Imidazol-5-il-anilinopirimidinas como agentes inhibidores de la proliferacion celular - Google Patents

Imidazol-5-il-anilinopirimidinas como agentes inhibidores de la proliferacion celular

Info

Publication number
AR047702A1
AR047702A1 ARP050100414A ARP050100414A AR047702A1 AR 047702 A1 AR047702 A1 AR 047702A1 AR P050100414 A ARP050100414 A AR P050100414A AR P050100414 A ARP050100414 A AR P050100414A AR 047702 A1 AR047702 A1 AR 047702A1
Authority
AR
Argentina
Prior art keywords
alkyl
carbamoyl
heterocyclyl
sulfamoyl
amino
Prior art date
Application number
ARP050100414A
Other languages
English (en)
Inventor
David Michael Andrews
Ray Finlay
Clive Green
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0402277A external-priority patent/GB0402277D0/en
Priority claimed from GB0411998A external-priority patent/GB0411998D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR047702A1 publication Critical patent/AR047702A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

Compuestos, sus sales aceptables para uso farmacéutico, procesos para su preparacion y su uso como medicamento, particularmente medicamentos para producir un efecto inhibidor del ciclo celular (anti-proliferacion celular) en un animal de sangre caliente, tal como el hombre. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1), en donde: el Anillo A es un anillo saturado de 4-7 miembros unido a nitrogeno que contiene opcionalmente un átomo de nitrogeno, oxígeno o azufre adicional; en donde si el Anillo A contiene un átomo de nitrogeno adicional dicho nitrogeno puede ser opcionalmente sustituido por R7; R1 es halo, nitro, ciano, hidroxi, amino, carboxi, carbamoilo, mercapto, alquilo C1-6, alcoxi C1-6, alquenilo C2-6 o alquinilo C2-6; p es 0-4; en donde los valores de R1 pueden ser iguales o diferentes; R2 se selecciona entre halo, nitro, ciano, hidroxi, trifluorometoxi, amino, carboxi, carbamoilo, mercapto, azido, sulfamoilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcanoilo C1-6, N-(alquil C1-6)carbamoilo, N,N-(alquil C1-6)2carbamoilo, carbociclil-R34-, heterociclil-R35-, alquil C1-6S(O)a en donde a es entre 0 y 2, alcoxicarbonilo C1-6, N-(alquil C1-6)sulfamoilo o N,N-(alquil C1-6)2sulfamoilo; en donde R2 puede estar opcionalmente sustituido en forma independiente sobre carbono por uno o más R8; o R2 es -NHR9, -NR1R11 o -O-R12; q es 0-2; en donde los valores de R2 pueden ser iguales o diferentes; R3 es halo, nitro, ciano, hidroxi, trifluorometilo, trifluorometoxi, amino, carboxi, carbamoilo, mercapto, sulfamoilo, alquilo C1-3, alquenilo C2-3, alquinilo C2-3, alcoxi C1-3, alcanoilo C1-3, N-(alquil C1-3)amino, N,N-(alquil C1-3)2amino, alcanoilamino C1-3, N- (alquil C1-3)carbamoilo, N,N-(alquil C1-3)2carbamoilo, alquil C1-3S(O)a en donde a es entre 0 y 2, N-(alquil C1-3)sulfamoilo o N,N-(alquil C1-3)2sulfamoilo; en donde R3 puede estar opcionalmente sustituidos en forma independiente sobre carbono por uno o más R13; n es entre 0 y 2, en donde los valores de R3 pueden ser iguales o diferentes; R4 es hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, carbociclilo o un heterociclilo unido a carbono; en donde R4 puede estar opcionalmente sustituido sobre carbono por uno o más R14; y en donde si dicho heterociclilo contiene una porcion -NH- dicho nitrogeno puede ser opcionalmente sustituido por un grupo seleccionado entre R15; R5 y R6 se seleccionan en forma independiente entre hidrogeno, halo, nitro, ciano, hidroxi, trifluorometoxi, amino, carboxi, carbamoilo, mercapto, sulfamoilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alcanoilo C1-6, alcanoiloxi C1-6, N-(alquil C1-6)amino, N,N-(alquil C1-6)2amino, alcanoilamino C1-6, N-(alquil C1-6)carbamoilo, N,N-(alquil C1-6)2carbamoilo, alquil C1-6S(O)a en donde a es entre 0 y 2, alcoxicarbonilo C1-6, N-(alquil C1-6)sulfamoilo, N,N-(alquil C1-6)2sulfamoilo, alquilsulfonilamino C1-6, cicloalquilo C3-8 o un grupo heterociclo saturado de 4-7 miembros; en donde R5 y R6 en forma independiente entre sí pueden estar opcionalmente sustituidos sobre carbono por uno o más R16; y en donde si un grupo heterocíclico saturado de 4-7 miembros contiene una porcion - NH- dicho nitrogeno puede ser opcionalmente sustituido por un grupo seleccionado entre R17; R7, R9, R10, R11 y R12 se selecciona en forma independiente entre alquilo C1-6, alcanoilo C1-6, alquilsulfonilo C1-6, alquenilsulfonilo C2-6, alquinilsulfonilo C2-6, alcoxicarbonilo C1-6, carbamoilo, N-(alquil C1-6)carbamoilo, N,N-(alquil C1-6)carbamoilo, carbociclilo, heterociclilo, carbociclil-R18- o heterociclil-R19-; en donde R7, R9, R10, R11 y R12 pueden estar opcionalmente sustituidos en forma independiente sobre carbono por un grupo seleccionado entre R20; y en donde si dicho heterociclilo contiene una porcion -NH- dicho nitrogeno puede ser opcionalmente sustituido por R21; R14 y R20 se seleccionan en forma independiente entre halo, nitro, ciano, hidroxi, amino, carboxi, carbamoilo, mercapto, sulfamoilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alqueniloxi C2-6, alquiniloxi C2-6, alcoxi C1-6-alcoxi C1-6, alcoxi C1-6-alcoxi C1-6-alcoxi C1-6, alcanoilo C1-6, alcanoiloxi C1-6, N-(alquil C1-6)amino, N,N-(alquil C1-6)2amino, alcanoilamino C1-6, N-(alquil C1-6)carbamoilo, N,N-(alquil C1-6)2carbamoilo, alquil C1-6S(O)a en donde a es entre 0 y 2, alcoxicarbonilo C1-6, N-(alquil C1- 6)sulfamoilo, N,N-(alquil C1-6)2sulfamoilo, alquilsulfonilamino C1-6, carbociclilo, heterociclilo, carbociclil-alquil C1-6-R22-, heterociclil-alquil C1-6-R23-, carbociclil-R24- o heterociclil-R25-, en donde R14 y R20 pueden estar opcionalmente sustituidos en forma independiente sobre carbono por uno o más R26; y en donde si dicho heterociclilo contiene una porcion -NH- dicho nitrogeno puede ser opcionalmente sustituido por un grupo seleccionado entre R27; R18, R19, R22, R23, R24, R25, R34 o R35 se seleccionan en forma independiente -O-, -N(R28)-, -C(O)-, -N(R29)C(O)-, -C(O)N(R30)-, -S(O)s-, -SO2N(R31)- o -N(R32)SO2-; en donde R28, R29, R30, R31 y R32 se seleccionan en forma independiente entre hidrogeno o alquilo C1-6 y s es 0-2; R15, R17, R21 y R27 y se seleccionan en forma independiente entre alquilo C1-6, alcanoilo C1-6, alquilsulfonilo C1-6, alcoxicarbonilo C1-6, carbamoilo, N-(alquil C1-6)carbamoilo, N,N-(alquil C1-6)carbamoilo, bencilo, benciloxicarbonilo, benzoilo y fenilsulfonilo; en donde R15, R17, R21 y R27 en forma independiente entre sí pueden estar opcionalmente sustituidos sobre carbono por uno o más R33; y R8, R13, R16, R26 y R33 se seleccionan en forma independiente entre halo, nitro, ciano hidroxi, trifluorometoxi, trifluorometilo, amino, carboxi, carbamoilo, mercapto, sulfamoilo, metilo, etilo, metoxi, etoxi, acetilo, acetoxi, metilamino, etilamino, dimetilamino, dietilamino, N-metil-N-etilamino, acetilamino, N-metilcarbamoilo, N- etilcarbamoilo, N,N-dimetilcarbamoilo, N,N-dietilcarbamoilo, N-metil-N-etilcarbamoilo, metiltio, etiltio, metilsulfinilo, etilsulfinilo, mesilo, etilsulfonilo, metoxicarbonilo, etoxicarbonilo, N-metilsulfamoilo, N-etilsulfamoilo, N,N- dimetilsulfamoilo, N,N-dietilsulfamoilo o N-metil-N-etilsulfamoilo; o una sal aceptable para uso farmacéutico o un éster hidrolizable en vivo del mismo.
ARP050100414A 2004-02-03 2005-02-03 Imidazol-5-il-anilinopirimidinas como agentes inhibidores de la proliferacion celular AR047702A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0402277A GB0402277D0 (en) 2004-02-03 2004-02-03 Chemical compounds
GB0411998A GB0411998D0 (en) 2004-05-28 2004-05-28 Chemical compounds

Publications (1)

Publication Number Publication Date
AR047702A1 true AR047702A1 (es) 2006-02-08

Family

ID=34839910

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100414A AR047702A1 (es) 2004-02-03 2005-02-03 Imidazol-5-il-anilinopirimidinas como agentes inhibidores de la proliferacion celular

Country Status (16)

Country Link
US (1) US7655652B2 (es)
EP (1) EP1748999A1 (es)
JP (1) JP2007522145A (es)
KR (1) KR20060129040A (es)
AR (1) AR047702A1 (es)
AU (1) AU2005210248A1 (es)
BR (1) BRPI0507351A (es)
CA (1) CA2554076A1 (es)
CO (1) CO5700716A2 (es)
IL (1) IL176942A0 (es)
NO (1) NO20063905L (es)
RU (1) RU2006131557A (es)
TW (1) TW200528101A (es)
UY (1) UY28733A1 (es)
WO (1) WO2005075461A1 (es)
ZA (1) ZA200606243B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR058073A1 (es) * 2005-10-03 2008-01-23 Astrazeneca Ab Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
JP2009541285A (ja) * 2006-06-21 2009-11-26 アストラゼネカ アクチボラグ 化学化合物
WO2008008234A1 (en) 2006-07-07 2008-01-17 Targegen, Inc. 2-amino-5-substituted pyrimidine inhibitors
CA2670375A1 (en) 2006-12-08 2008-06-12 F. Hoffmann-La Roche Ag Substituted pyrimidines and their use as jnk modulators
DK2265607T3 (en) 2008-02-15 2017-03-13 Rigel Pharmaceuticals Inc PYRIMIDIN-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES
AR076300A1 (es) 2009-04-15 2011-06-01 Astrazeneca Ab Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades.
EP2836482B1 (en) * 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
CN112521369A (zh) 2013-03-13 2021-03-19 福马治疗股份有限公司 用于抑制fasn的化合物及组合物
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
KR102030886B1 (ko) * 2016-09-23 2019-10-10 재단법인 대구경북첨단의료산업진흥재단 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
EP3571193B1 (en) 2017-01-23 2021-12-01 Cadent Therapeutics, Inc. Potassium channel modulators
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659363A (en) 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
US4946956A (en) 1988-09-21 1990-08-07 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
JP2932693B2 (ja) 1992-10-05 1999-08-09 宇部興産株式会社 ピリミジン化合物
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
NZ273617A (en) 1993-10-01 1996-11-26 Ciba Geigy Ag N-phenyl-2-pyrimidineamine derivatives pharmaceutical compositions
WO1995009847A1 (en) 1993-10-01 1995-04-13 Ciba-Geigy Ag Pyrimidineamine derivatives and processes for the preparation thereof
PT672042E (pt) 1993-10-01 2006-08-31 Novartis Ag Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
US5750531A (en) 1994-08-13 1998-05-12 Yuhan Corporation Pyrimidine derivatives and processes for the preparation thereof
DE69630214T2 (de) 1995-03-10 2004-07-15 Berlex Laboratories, Inc., Richmond Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5658903A (en) 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
JP2000507558A (ja) 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
JP2000511883A (ja) 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
ATE294174T1 (de) 1996-06-10 2005-05-15 Merck & Co Inc Substituierte imidazole mit cytokinin- inhibirender wirkung
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
WO1998016230A1 (en) 1996-10-17 1998-04-23 Smithkline Beecham Corporation Methods for reversibly inhibiting myelopoiesis in mammalian tissue
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
CA2271157A1 (en) 1997-02-05 1998-08-06 Warner-Lambert Company Pyrido[2,3-d]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
DE19710435A1 (de) 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
EP0988301B1 (en) 1997-06-12 2006-08-09 Aventis Pharma Limited Imidazolyl-cyclic acetals
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
EP1019391A1 (en) 1997-10-02 2000-07-19 Merck & Co. Inc. Inhibitors of prenyl-protein transferase
EP1021173A1 (en) 1997-10-10 2000-07-26 Imperial College Innovations Limited Use of csaid?tm compounds for the management of uterine contractions
US6432963B1 (en) 1997-12-15 2002-08-13 Yamanouchi Pharmaceutical Co., Ltd. Pyrimidine-5-carboxamide derivatives
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
ES2193660T3 (es) 1998-03-27 2003-11-01 Janssen Pharmaceutica Nv Derivados de pirimidina inhibidores de vih.
GB9806739D0 (en) 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
AU5438499A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
SK3842001A3 (en) 1998-09-18 2002-04-04 Basf Ag Pyrrolopyrimidines as protein kinase inhibitors (revised)
HUP0200355A3 (en) 1998-09-18 2004-07-28 Abbott Gmbh & Co Kg 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
US6531477B1 (en) 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
WO2000025780A1 (en) 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
AU6476599A (en) 1998-11-03 2000-05-22 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
CN1353713A (zh) 1999-02-01 2002-06-12 Cv治疗公司 依赖细胞周期蛋白的激酶2和IκB－α的嘌呤抑制剂
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6627633B2 (en) 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
WO2001030778A1 (en) 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
KR20020050294A (ko) 1999-11-22 2002-06-26 피터 기딩스 신규화합물
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
WO2001047921A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
MXPA02007957A (es) 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
AU2001242629B2 (en) * 2000-03-29 2005-08-11 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
EP1423388B1 (en) * 2001-02-20 2008-12-03 AstraZeneca AB 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
SE0100569D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab New compounds
GB0107901D0 (en) * 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
CA2446864C (en) 2001-05-16 2011-02-15 Vertex Pharmaceuticals Incorporated Inhibitors of src and other protein kinases
RS94703A (en) 2001-05-29 2007-02-05 Schering Aktiengesellschaft, Cdk inhibiting pyrimidines, production thereof and their use as medicaments
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2003011837A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
GB0123589D0 (en) 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
JP2005508955A (ja) 2001-10-05 2005-04-07 スミスクライン ビーチャム コーポレーション ヘルペスウイルス感染の治療で使用されるためのイミダゾ−ピリジン誘導体
KR20040048920A (ko) 2001-11-01 2004-06-10 얀센 파마슈티카 엔.브이. 글리코겐 신타아제 키나제 3-베타 저해제(ｇｓｋ저해제)로서의 헤테로아릴 아민
CN1582284A (zh) 2001-11-07 2005-02-16 霍夫曼-拉罗奇有限公司 氨基嘧啶类和吡啶类化合物
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
JP2005524672A (ja) 2002-03-09 2005-08-18 アストラゼネカ アクチボラグ Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
EP1554269A1 (en) 2002-07-09 2005-07-20 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0226582D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
CA2523125A1 (en) 2003-03-25 2004-10-14 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
EP1605946B1 (en) 2003-03-25 2008-05-28 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
MX2007004488A (es) 2004-10-13 2007-09-11 Wyeth Corp Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos.

Also Published As

Publication number Publication date
CO5700716A2 (es) 2006-11-30
IL176942A0 (en) 2006-12-10
BRPI0507351A (pt) 2007-07-03
RU2006131557A (ru) 2008-03-10
ZA200606243B (en) 2008-01-08
EP1748999A1 (en) 2007-02-07
WO2005075461A1 (en) 2005-08-18
NO20063905L (no) 2006-10-27
AU2005210248A1 (en) 2005-08-18
CA2554076A1 (en) 2005-08-18
UY28733A1 (es) 2005-09-30
JP2007522145A (ja) 2007-08-09
US20070161615A1 (en) 2007-07-12
US7655652B2 (en) 2010-02-02
TW200528101A (en) 2005-09-01
KR20060129040A (ko) 2006-12-14

Similar Documents

Publication Publication Date Title
AR047702A1 (es) Imidazol-5-il-anilinopirimidinas como agentes inhibidores de la proliferacion celular
AR063643A1 (es) Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticas
AR054183A1 (es) Derivados de piridincarboxamida y su uso como agentes anticancerigenos. procesos de obtencion y composiciones farmaceuticas.
AR053683A1 (es) Derivados de piperidina con actividad antibacteriana
AR049662A1 (es) Derivados de 1,3-fenilendiamina con efecto inhibitorio de b-raf; un metodo para su preparacion, composiciones farmaceuticas que los contienen y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer
AR055249A1 (es) Derivados de quinazolinas, procesos de obtencion y composiciones farmaceuticas
AR040408A1 (es) Derivados de benzotiadiazepina, procesos para su preparacion y composiciones farmaceuticas que los contienen
AR064130A1 (es) Derivados de tiazoles y piridinas como antibacterianos. composiciones farmaceuticas.
AR053992A1 (es) Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
AR052170A1 (es) Derivados de pirimidina utiles por su actividad anti-proliferacion celular
AR064208A1 (es) Derivados de piridin-3-il-quinazolinas como inhibidores de b-raf. procesos de obtencion y composiciones farmaceuticas.
AR056354A1 (es) DERIVADOS DE PIRAZOL, UN MÉTODO DE PREPARACIoN DEL COMPUESTO, COMPOSICIoN FARMACÉUTICA Y PREPARACIoN DE UN MEDICAMENTO
AR050545A1 (es) Derivados de quinazolinonas y su uso como inhibidores de b-raf
AR056184A1 (es) Compuestos derivados de pirazol, composicion farmaceutica en base a aquellos y su uso para la fabricacion de medicamentos
AR062406A1 (es) Derivados de quinazolina como inhibidores de b-raf
AR070493A1 (es) Derivados heterociclicos de urea, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de infecciones bacterianas.
AR072045A1 (es) Derivados heterociclicos de urea y metodos para utilizarlos
AR061653A1 (es) Compuestos inhibidores de gsk3(glucogeno sintasa quinasa 3)
AR046779A1 (es) Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer.
AR072047A1 (es) Compuestos heterociclicos utiles para inhibir la adn girasa
AR056210A1 (es) 4-(3-aminopirazol)pirimidina para uso como inhibidores de tirosina-quinasa
AR056556A1 (es) Imidazo(1,2-a)piridina con actividad antiproliferacion celular
AR031251A1 (es) Derivado de pirimidina, composicion farmaceutica que lo comprende, su uso en la fabricacion de un medicamento y proceso de preparacion
AR046615A1 (es) Pirrolidinas 3-(benzoil)-n-aciladas, como inhibidores de 11-beta-hsd1, utiles en el tratamiento de desordenes metabolicos
AR076899A1 (es) Derivados heterociclicos de la urea, composiciones farmaceuticas y su uso en el tratamiento de infecciones bacterianas

Legal Events

Date Code Title Description
FB Suspension of granting procedure